Gentamicin Dosing for Wound Infections
For wound infections in patients with normal renal function, gentamicin should be dosed at 5-7 mg/kg once daily IV/IM, based on actual body weight (or adjusted body weight in obese patients), with therapeutic drug monitoring to maintain trough levels <0.5-1 mg/L to minimize nephrotoxicity. 1, 2
Standard Dosing Regimen
Initial Dosing
- Loading dose: 5-7 mg/kg once daily for patients with preserved renal function 1
- Base dosing on actual body weight (or adjusted body weight in obese patients, not total body weight) 2
- The FDA-approved standard dose is 3 mg/kg/day divided every 8 hours, but once-daily dosing (5-7 mg/kg) is preferred in modern practice for serious infections, including wound infections, as it optimizes peak concentration-dependent killing while reducing nephrotoxicity 1, 2
Therapeutic Targets
- Peak concentration (Cmax): 4-6 mcg/mL with traditional dosing; with once-daily dosing, aim for Cmax/MIC ratio of 8-10 2
- Trough concentration: <0.5-1 mg/L (ideally <0.5 mg/L) to minimize nephrotoxicity; absolutely keep <2 mg/L 1, 2
- Measure peak at 30-60 minutes post-IM injection or post-IV infusion 2
Renal Function Adjustments
This is critical—gentamicin dosing must be adjusted based on creatinine clearance:
Normal Renal Function (CrCl ≥60 mL/min)
Mild Impairment (CrCl 40-59 mL/min)
- Dose: 5-7 mg/kg every 36 hours 3
- Maintain same loading dose but extend interval
- Monitor drug levels closely 4, 2
Moderate Impairment (CrCl 20-39 mL/min)
- Dose: 5-7 mg/kg every 48 hours 3
- Only 15% achieve target trough with 24-hour dosing, necessitating extended intervals 3
Severe Impairment (CrCl <20 mL/min)
- Consult infectious disease specialist 4
- Aminoglycosides may not clear for several days; extended interval dosing not appropriate 1
- Consider alternative antibiotics
Therapeutic Drug Monitoring
TDM is essential for wound infections requiring >1 dose:
- Mandatory monitoring for patients receiving multiple doses to prevent nephrotoxicity 1
- Check trough levels before next dose to ensure <0.5-1 mg/L 2
- In critically ill patients, altered pharmacokinetics (increased volume of distribution from fluid resuscitation) may result in subtherapeutic levels—monitor both peak and trough 1
- Burn patients have significantly decreased half-life and lower serum concentrations; TDM is critical 2
Duration of Therapy
- Limit treatment to 7-10 days for most wound infections 2
- For complicated intra-abdominal infections with adequate source control: 4-7 days maximum 5
- Prolonged therapy (>10 days) increases toxicity risk—monitor renal, auditory, and vestibular function if extended treatment necessary 2
Special Populations
Critically Ill/Septic Patients
- Use 7 mg/kg loading dose due to expanded extracellular volume from fluid resuscitation 1
- Failure to achieve adequate peak concentrations on initial dosing associated with clinical failure 1
- Volume of distribution significantly increased in sepsis—standard doses often subtherapeutic 1
Obese Patients
- Calculate dose using adjusted body weight, not total body weight 2
- Adjusted body weight = IBW + 0.4(TBW - IBW)
Burn Patients
- Significantly altered pharmacokinetics with decreased half-life 2
- May require higher or more frequent dosing
- TDM is mandatory 2
Common Pitfalls to Avoid
Don't use multiple daily dosing (every 8 hours) for serious infections—once-daily dosing provides superior peak concentrations with equal or less nephrotoxicity 1
Don't underdose critically ill patients—use 7 mg/kg, not 5 mg/kg, due to increased volume of distribution 1
Don't forget to adjust for renal function—even mild impairment (CrCl 40-59) requires extended intervals to 36 hours 3
Don't skip TDM in patients receiving >1 dose—nephrotoxicity occurs in ~4% of patients, with 25% being irreversible (1% overall irreversible nephrotoxicity) 3
Don't continue beyond 7-10 days without compelling reason—toxicity risk increases significantly with prolonged therapy 2
Topical Gentamicin for Wounds
For superficial wound infections or as adjunct therapy, topical gentamicin ointment/cream can be applied directly to wound beds 6, 7. This approach:
- Reduces bacterial biofilm
- Decreases inflammation
- Safe with no systemic absorption concerns
- Can be delivered via specialized wound devices for enhanced efficacy 7
However, systemic IV/IM gentamicin remains the standard for serious wound infections requiring aminoglycoside coverage.